Package 55513-132-01

{"route": ["INTRAVENOUS"], "spl_id": "0921bf2c-8d88-4b27-bcf2-7e776577ffe1", "openfda": {"nui": ["N0000175661", "N0000020008"], "unii": ["P188ANX8CK"], "rxcui": ["2174804", "2174809", "2257297", "2257300"], "spl_set_id": ["9a94f5b2-b84e-4987-8ea1-c4346db5a5fa"], "pharm_class_epc": ["HER2/neu Receptor Antagonist [EPC]"], "pharm_class_moa": ["HER2/Neu/cerbB2 Antagonists [MoA]"], "manufacturer_name": ["Amgen, Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-01)  / 20 mL in 1 VIAL, MULTI-DOSE", "package_ndc": "55513-132-01", "marketing_start_date": "20190611"}, {"sample": false, "description": "1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-21)  / 20 mL in 1 VIAL, MULTI-DOSE", "package_ndc": "55513-132-21", "marketing_start_date": "20250701"}], "brand_name": "Kanjinti", "product_id": "55513-132_0921bf2c-8d88-4b27-bcf2-7e776577ffe1", "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION", "pharm_class": ["HER2/Neu/cerbB2 Antagonists [MoA]", "HER2/neu Receptor Antagonist [EPC]"], "product_ndc": "55513-132", "generic_name": "trastuzumab-anns", "labeler_name": "Amgen, Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Kanjinti", "active_ingredients": [{"name": "TRASTUZUMAB", "strength": "420 mg/20mL"}], "application_number": "BLA761073", "marketing_category": "BLA", "marketing_start_date": "20190611", "listing_expiration_date": "20261231"}